

Reviewer Relationships With Industry and Other Entities (Comprehensive) — 2018 ACC Expert Consensus Decision Pathway on Managing CVD Risk in Diabetes

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
John B. Buse	Official Reviewer—ADA	University of North Carolina School of Medicine—Director, Diabetes Care	<ul style="list-style-type: none"> • Neurimmune* 	None	<ul style="list-style-type: none"> • Mellitus Health • PhaseBio • Stability Health 	<ul style="list-style-type: none"> • Novo Nordisk† • Sanofi-Aventis† • vTv Therapeutics† 	<ul style="list-style-type: none"> • Adocia* • AstraZeneca* • Eli Lilly* • MannKind* • NovaTarg* • Novo Nordisk* • Senseonics* • vTv Therapeutics* 	None
Christopher P. Cannon	Official Reviewer—ADA	Brigham and Women's Hospital, Harvard Medical School—Professor of Medicine	<ul style="list-style-type: none"> • Alnylam • Amarin • Amgen† • AstraZeneca† • Boehringer-Ingelheim† • Bristol Myers Squibb • Kowa • Merck† • Pfizer • Regeneron/Sanofi† 	None	None	<ul style="list-style-type: none"> • Amgen† • Bristol-Myers Squibb† • Boehringer Ingelheim† • Daiichi Sankyo† • Janssen Pharmaceuticals† • Merck† • Takeda† 	None	None
Jill Crandall	Official Reviewer—ADA	Albert Einstein College of Medicine—Professor, Department of Medicine (Endocrinology)	None	None	None	None	None	None
David D'Alessio	Official Reviewer—ADA	Duke Molecular Physiology Institute—Associate Director	<ul style="list-style-type: none"> • Eli Lilly 	None	None	<ul style="list-style-type: none"> • Eli Lilly† 	<ul style="list-style-type: none"> • American Diabetes Association† • Endocrine Society • vTv Therapeutics‡ 	None

Ian de Boer	Official Reviewer— ADA	University of Washington (Seattle)—Associate Professor of Medicine, Division of Nephrology	<ul style="list-style-type: none"> • Boehringer Ingelheim • Ironwood 	None	None	None	<ul style="list-style-type: none"> • ADA* 	None
Judith Fradkin	Official Reviewer— ADA	National Institute of Diabetes and Digestive and Kidney Diseases—Director of the Division of Diabetes, Endocrinology, and Metabolic Diseases	None	None	None	None	None	None
Ty J. Gluckman	Official Reviewer— ACC BOG	Providence Heart and Vascular Institute— Medical Director	<ul style="list-style-type: none"> • Boehringer Ingelheim 	None	None	None	None	None
Sherita Hill Golden	Official Reviewer— ADA	Johns Hopkins University School of Medicine, Welch Center for Prevention, Epidemiology, and Clinical Research—Hugh P. McCormick Family Professor of Endocrinology and Metabolism	None	None	None	<ul style="list-style-type: none"> • Merck† 	<ul style="list-style-type: none"> • ADA* 	None
Joshua J. Neumiller	Official Reviewer— ADA	Washington State University, College of Pharmacy—Vice-Chair & Associate Professor, Department of Pharmacotherapy; Editor- in-Chief, <i>Diabetes Spectrum</i>	<ul style="list-style-type: none"> • ADA† 	None	None	None	None	None
Barbara S. Wiggins	Official Lead Reviewer—Task Force on Expert Consensus Decision Pathways	Medical University of South Carolina—Clinical Pharmacy Specialist Cardiology, Department of Pharmacy Services	None	None	None	None	None	None
Seth J. Baum	Organizational Reviewer—ASPC	American Society for Preventive Cardiology— President	<ul style="list-style-type: none"> • Akcea† • Amgen† • Cleveland Heart Lab† • Novo Nordisk† • Regeneron† 	<ul style="list-style-type: none"> • Aralez† • Boehringer Ingelheim† 	None	None	<ul style="list-style-type: none"> • Excel Medical Clinical Trials† • Florida Atlantic University† • Northridge Heart Association† 	None

			<ul style="list-style-type: none"> • Sanofi-Aventis † 					
James M. Falko	Organizational Reviewer—NLA	University of Colorado— Clinical Professor of Medicine	<ul style="list-style-type: none"> • Merck • Akcea • Alexion • Kowa 	None	None	None	None	None
Stuart T. Haines	Organizational Reviewer—APA	University of Mississippi School of Pharmacy— Professor, Department of Pharmacy Practice; Director, Pharmacy Professional Development	None	None	None	<ul style="list-style-type: none"> • Rx Instructional Systems† 	<ul style="list-style-type: none"> • American Association of Colleges of Pharmacy* 	None
Barbara A. Hutchinson	Organizational Reviewer—ABC	Chesapeake Cardiac Care—President; Association of Black Cardiologists—Immediate Past President	None	None	None	None	None	None
Daniel L. Hurley	Organizational Reviewer—AACE	Mayo Clinic—Consultant, Division of Endocrinology, Diabetes, Metabolism and Nutrition; Mayo Clinic College of Medicine & Science—Associate Professor of Medicine	None	None	None	None	None	None
Paul S. Jellinger	Organizational Reviewer—AACE	University of Miami Miller School of Medicine —Professor of Clinical Medicine; The Center for Diabetes & Endocrine Care—Cardiologist	None	<ul style="list-style-type: none"> • Amgen† • AstraZeneca† • Janssen† • Merck† • Merck† • Novo Nordisk† • Regeneron† 	None	None	None	None
Joshua Joseph	Organizational Reviewer—AHA	The Ohio State University Wexner Medical Center— Assistant Professor of Medicine,	None	None	None	None	None	None
Cynthia A. Lamendola	Organizational Reviewer—PCNA	Division of Endocrinology, Diabetes and Metabolism	None	None	None	<ul style="list-style-type: none"> • Elger Biopharmaceutical † • Janssen R&D 	None	None

Anthony L. McCall	Organizational Reviewer—Endocrine Society	Stanford Medicine and Stanford Health Care—Nurse Practitioner; Clinical Research Study Coordinator	<ul style="list-style-type: none"> • Eli Lilly 	None	None	<ul style="list-style-type: none"> • NIH* 	None	None
Joanna Mitri	Organizational Reviewer—Joslin Diabetes Center	University of Virginia School of Medicine—Professor of Medicine & Diabetes/Endocrinology (Emeritus); Cornell University—Professor of Nutritional Sciences, Cornell University Cornell	<ul style="list-style-type: none"> • Cuthealth* • National Dairy Council 	<ul style="list-style-type: none"> • Kowa* • National Dairy Council* 	None	None	None	None
Mary H. Parker	Organizational Reviewer—ASHP	Durham VA Medical Center—Acting Associate Chief of Staff for Ambulatory Care	None	None	None	None	None	None
David Sperling	Organizational Reviewer—AAFP	Northeast Ohio Medical University—Associate Professor, Department of Family and Community Medicine	None	None	None	None	None	None
Veronica Wilbur	Organizational Reviewer—AANP	Westchester University—Assistant Professor Graduate Nursing	None	None	None	None	None	None
Suzanne V. Arnold	Content Reviewer—Roundtable Participant	Saint Luke's Mid America Heart Institute/University of Missouri-Kansas City—Associate Professor	None	None	None	None	None	None
Michael Blaha	Content Reviewer—ACC Expert	Johns Hopkins Ciccarone Center for the Prevention of Heart Disease—Director of Clinical Research	<ul style="list-style-type: none"> • ACC • Akcea • Amgen • MedImmune • Novartis • Regeneron • Sanofi • Siemens† 	None	None	<ul style="list-style-type: none"> • AHA* • FDA* • NIH* 	None	None
Roger S. Blumenthal	Content Reviewer—Co-Chair, 2019 Prevention Guideline Writing	Johns Hopkins Hospital Ciccarone Preventive Cardiology Center—Pollin Professor of Cardiology	None	None	None	None	None	None

	Committee							
Matthew Aaron Cavender	Content Reviewer–Roundtable Participant	University of North Carolina at Chapel Hill—Assistant Professor of Medicine, Interventional Cardiology	<ul style="list-style-type: none"> • AstraZeneca • Boehringer Ingelheim† • Chiesi • Janssen† • Merck • Novo Nordisk • Sanofi-Aventis† 	None	None	<ul style="list-style-type: none"> • Abbott Laboratories* • AstraZeneca* • Chiesi* • GlaxoSmithKline* • Novartis* • Takeda* • The Medicines Company* 	<ul style="list-style-type: none"> • St. Jude Medical‡ 	None
Deborah Croy	Content Reviewer–Roundtable Participant	Bland County Medical Clinic—Adult Cardiovascular Nurse Practitioner	None	None	None	None	None	None
Prakash Deedwania	Content Reviewer–Diabetes & Cardiometabolic Syndrome Working Group	University of California San Francisco Fresno—Chief of Cardiology	<ul style="list-style-type: none"> • Amgen† • Pfizer 	None	None	None	<ul style="list-style-type: none"> • Novartis‡ 	None
Robert N. Piana	Content Reviewer–Task Force on Expert Consensus Decision Pathways	Vanderbilt University Medical Center—Professor of Medicine (Cardiology)	<ul style="list-style-type: none"> • Axio • BCRI • Gore 	None	None	<ul style="list-style-type: none"> • Abbott Laboratories (DSMB)† 	<ul style="list-style-type: none"> • Cardiovascular Peer Review, LLC† • Doris Duke Charitable Foundation/Washington University‡ • Duke Clinical Research Institute/OrbusNeich‡ • St. Jude Medical‡ 	None
Jorge Plutzky	Content Reviewer–Roundtable Participant	Brigham and Women's Hospital, Harvard Medical School—Director, The Vascular Disease Prevention Program	<ul style="list-style-type: none"> • Amgen† • AstraZeneca • Boehringer Ingelheim • Cowen • Janssen Pharmaceuticals† • Novo Nordisk† • Sanof † 	None	<ul style="list-style-type: none"> • Vivus† 	None	None	None

Carla Weidner	Content Reviewer– Cardiovascular Team Council	St. Luke’s University Health Network—Cardiac Nurse Practitioner	None	None	None	None	None	None
Deborah J. Wexler	Content Reviewer– ACC Expert	Harvard Medical School— Associate Professor of Medicine; Massachusetts General Hospital— Associate Clinical Chief, Diabetes Unit	None	None	None	None	None	None
Nathan D. Wong	Content Reviewer– Prevention Council and Roundtable Participant	Brigham and Women’s Hospital, Harvard Medical School—Director, The Vascular Disease Prevention Program	<ul style="list-style-type: none"> • Akcea • Pfizer 	<ul style="list-style-type: none"> • Sanofi 	None	<ul style="list-style-type: none"> • Amarin† • Amgen† • Boehringer Ingelheim† • Gilead Sciences† • Pfizer† 	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

*No financial benefit.

†Significant relationship.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

AACE=American Association of Clinical Endocrinology; AAFP=American Academy of Family Physicians; AANP=American Association of Nurse Practitioners; ABC=Association of Black Cardiologists; ACC=American College of Cardiology; ADA=American Diabetes Association; AHA=American Heart Association; APA=American Pharmacists Association; ASHP=American Society of Health-System Pharmacists; ASPC=American Society for Preventive Cardiology; BOG=Board of Governors; CVD=cardiovascular disease; DSMB=Data Safety Monitoring Board; NIH=National Institutes of Health; FDA=US Food and Drug Administration; NLA=National Lipid Association; PCNA=Preventive Cardiovascular Nurses Association; VA=Veterans Administration.